Briefing
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
24-month EFS 67.8% vs 59.8%, HR 0.68 (0.56-0.82), P<0.001.
- Design: Phase 3, cisplatin-eligible MIBC
- n: 1063 (533 durvalumab, 530 comparison)
- Assay: n/a (clinical end points)